Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1-20. **canceled**

21. **(previously presented)** The method of Claim 29 wherein the CGRP receptor is on a cell.

22. **(previously presented)** The method of Claim 29 wherein the CGRP receptor is cell free.

23. **(original)** The method of Claim 21 wherein the cell is in culture.

24. **(original)** The method of Claim 21 wherein the cell is part of a tissue.

25. **(original)** The method of Claim 21 wherein the cell is in an animal.

26. **(original)** The method of Claim 25 wherein the animal is a human.

27-28. **canceled**

29. **(previously presented)** A method for inhibiting CGRP binding to one or more CGRP receptors comprising contacting a CGRP receptor with a composition comprising a peptide having the general formula:

$$R^1\text{-}X\text{-}Z$$

wherein Z is a CGRP receptor-binding peptide, R^1 is an organic group, X is



and wherein R^2 and R^3 are independently H or an organic group and n is a whole integer between 1 and 10;
in an amount effective to inhibit CGRP binding to one or more CGRP receptors.

30. **(original)** The method of Claim 29 wherein Z is a peptide fragment of at least 15 amino acids from CGRP.

31. **(original)** The method of Claim 30 wherein Z comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

32. **(previously presented)** The method of Claim 29 wherein Z is an antagonist of human CGRP.

33. **(previously presented)** The method of Claim 29 wherein Z is an antagonist of α-CGRP or β-CGRP.

34. **(currently amended)** The method of Claim 33 wherein Z comprises ~~the~~ an amino acid sequence selected from the group consisting of SEQ ID NOS:6-17 and 23.

35. **(currently amended)** The method of Claim 33 wherein Z comprises ~~the~~ an amino acid sequence selected from the group consisting of SEQ ID NOS:18-22.

36. **(original)** The method of claim 29 wherein Z is a CGRP antagonist peptide fragment selected from the group consisting of amylin, CGRP and adrenomedullin.

37. **(original)** The method of Claim 29 wherein R^1 is an aromatic group, a heterocyclic group or an alkyl group and R^2 and R^3 are independently H, an aromatic group or an alkyl group.

38. **(original)** The method of Claim 37 wherein R^1 is a C1-C4 alkyl group.

39. **(original)** The method of Claim 38 wherein R^1 is a fluoroalkyl.

40. **(original)** The method of Claim 38 wherein R^2 and R^3 are independently H, a C1-C4 alkyl group or a phenyl moiety.

41. **(original)** The method of Claim 38 wherein R^1 is a C5-C10 aromatic group, a C5-C9 heterocyclic group or a C1-C4 alkyl group.

42. **(original)** The method of Claim 41 wherein R^2 and R^3 are independently H or a C5-C10 aromatic group or a C1-C4 alkyl group.

43. **(original)** The method of Claim 37 wherein R^1 has the general formula:



and wherein R^4-R^8 are each independently selected from the group of H, fluoro, chloro, bromo, iodo, nitro, nitrile (cyano), amino, N-methyl amino, N,N-dimethyl amino, hydroxy, methoxy, thiomethoxy (S-methyl), methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, trifluoromethyl, trifluoromethoxy, vinyl, acetamido, phenyl, toluyl, and methoxyphenyl.

44. **(original)** The method of Claim 43 wherein R^6 is trifluoromethyl and R^4, R^5, R^7 and R^8 are F.

45. **(previously presented)** The method of Claim 37 wherein R^1 is



and wherein Y is selected from the group consisting of O, NH, and S.

46. **(previously presented)** The method of Claim 43 wherein the peptide is a CGRP antagonist having at least 15 consecutive amino acids selected from a protein from the group consisting of N-α-benzoyl-α-CGRP, N-α-benzyl-β-CGRP, N-α-benzoyl-β-CGRP and N-α-benzyl-α CGRP, dibenzyl-h-α-CGRP and dibenzyl-h-β-CGRP.

47. **(original)** The method of Claim 37 wherein R^1 is selected from the group consisting of:



and wherein X is selected from the group consisting of C and N.

48-53. **canceled**

54. **(previously presented)** The method of claim 29 wherein Z is a vasoactive peptide.

55. **(previously presented)** The method of claim 54 wherein Z is an antagonist of human CGRP.